Subject:
- Active Substance: Difelikefalin
- Name: Kapruvia®
- Therapeutic area: Pruritus
- Pharmaceutical company: Fresenius Medical Care Nephrologica Deutschland GmbH
Time table:
- Start: 01.10.2022
- Publication of assessment: 02.01.2023
- End of public hearing: 23.01.2023
- Final decision by G-BA: middle of March 2023
Comparative therapy:
- A patient-individual therapy taking into account prior therapies and the severity of symptoms